Zealand Pharma A/S and OTR Therapeutics have entered a multi-program strategic collaboration and licensing agreement to develop novel oral small-molecule therapies for metabolic diseases. The deal includes an initial payment of USD 20 million to OTR Therapeutics, which could increase to USD 30 million under predefined conditions. Total consideration may reach approximately USD 2.5 billion, with the majority tied to commercial milestones, plus tiered royalties on sales. This marks a significant modality shift for Zealand Pharma, which has historically focused on peptide-based drug development for obesity and metabolic health.

What Zealand Pharma gains by stepping beyond peptides and into small molecules

This collaboration signals a turning point in Zealand Pharma’s evolution as it diversifies beyond its peptide drug discovery foundation into the realm of small-molecule therapeutics. For a company with over two decades of expertise in peptide research and development, this marks a deliberate response to industry trends that favor oral formulations and flexible dosing formats in metabolic care.

Peptide-based treatments such as semaglutide have demonstrated exceptional efficacy in weight management and glycemic control. However, their injectable nature creates friction in long-term adherence, particularly in primary care settings. Zealand Pharma’s push into oral small molecules suggests a strategy to capture market segments that require less invasive delivery options while reducing dependency on cold-chain logistics and specialty care pathways.

This move is aligned with a broader industry pivot toward developing once-daily or even less frequent oral alternatives to injectable GLP-1 receptor agonists. The ability to offer a more convenient oral solution could improve early-stage intervention outcomes in patients with obesity or metabolic syndrome, areas still underserved by injectable-only regimens.

How OTR Therapeutics is positioning itself as a high-speed discovery partner

OTR Therapeutics, headquartered in Shanghai’s Zhangjiang Hi-Tech Park, may be relatively new, but it has been architected for rapid preclinical execution and innovation at scale. The company’s discovery engine is built on a proprietary platform optimized for oral small-molecule generation across difficult-to-drug metabolic targets. It blends advanced medicinal chemistry, computational design, and integration with regional translational science ecosystems in Asia, Europe, and North America.

The partnership structure assigns OTR Therapeutics lead responsibility for research and preclinical development, with Zealand Pharma managing clinical trials, regulatory interactions, and global commercialization. This allows each company to play to its strengths while minimizing duplication and preserving speed.

For Zealand Pharma, this provides plug-in access to a high-output discovery platform without committing to in-house infrastructure expansion. For OTR Therapeutics, the collaboration validates its platform with an established biotech player and introduces potential commercial-scale downstream upside. This dual benefit is emblematic of the rising prominence of agile discovery partners in the post-pandemic drug development economy.

Why this alliance stands apart from other metabolic drug deals in 2025

While the 2025 biopharmaceutical landscape is saturated with GLP-1 analog deals, this collaboration focuses on non-peptide oral agents for metabolic disorders. That places it in contrast to high-profile transactions such as Eli Lilly’s acquisition of Carmot Therapeutics or Novo Nordisk’s recent deepening of its peptide pipeline.

By pursuing targets outside of the incretin axis, Zealand Pharma and OTR Therapeutics could sidestep the receptor saturation, formulation challenges, and gastrointestinal tolerability issues increasingly associated with GLP-1-based therapies. This could allow for the development of complementary or entirely new therapeutic classes that widen the metabolic care paradigm beyond weight loss to include lipid disorders, insulin sensitivity modulation, and hepatic metabolism.

Clinicians observing the field note a growing interest in polypharmacy or combination regimens for metabolic diseases. Oral agents could be co-administered with GLP-1 injectables or serve as first-line options in patients with milder disease progression. The potential to integrate such molecules into fixed-dose combinations or long-term maintenance therapies adds another layer of appeal.

Where development, reimbursement, and regulatory risks remain significant

Despite the deal’s scale, it is rooted in early-stage co-discovery, which carries inherent uncertainty. The oral delivery route introduces unique challenges in bioavailability, metabolic stability, and off-target effects. While OTR Therapeutics’ platform is designed to address these issues, clinical validation remains unproven at this point.

Regulatory approval pathways for novel metabolic drugs, particularly those aiming to treat obesity as a standalone indication, are becoming increasingly complex. Agencies such as the U.S. Food and Drug Administration and the European Medicines Agency have tightened cardiovascular outcome requirements following concerns about long-term safety and durability of weight loss drugs.

Reimbursement dynamics also remain fluid. With the market flooded with expensive GLP-1s and tirzepatide-class drugs, payers may demand either superior outcomes or materially lower prices from new entrants. Without head-to-head comparative data, especially in large real-world patient cohorts, oral agents may struggle to gain rapid formulary access or win in health technology assessment reviews.

The cross-border nature of the alliance also introduces logistical complexities. Coordinating a discovery and development program across regulatory jurisdictions such as China, the United States, and the European Union requires harmonized timelines, data standardization, and strategic clinical site planning to meet trial diversity and inclusion expectations.

What this partnership signals about the next wave of metabolic drug development

Industry analysts suggest that this collaboration reflects the next logical phase in metabolic drug innovation: going beyond GLP-1 toward modality diversity, delivery innovation, and broader population engagement. As awareness of obesity and metabolic disease grows, therapeutic innovation must also evolve to meet the full spectrum of disease severity and patient preference.

The Zealand Pharma–OTR Therapeutics collaboration could become a template for future deals that combine platform biotechs and disease-area specialists in modular partnerships. By decoupling discovery from clinical development, the model allows for specialization, risk mitigation, and faster decision-making.

Investors watching Zealand Pharma may view this partnership as a lever to re-rate the company’s growth trajectory by injecting early-stage optionality into its pipeline. For OTR Therapeutics, this agreement places it firmly on the radar as a scalable discovery partner capable of unlocking substantial value beyond China’s biotech market.

The next set of milestones to watch include target nominations, proof-of-concept preclinical data, and eventual investigational new drug (IND) filings. If even one of these oral agents progresses to clinical trials with differentiated mechanisms or endpoints, the collaboration could have a ripple effect across the sector.

  drug discovery, GLP-1, metabolic disease, obesity, oral small molecules, OTR Therapeutics, peptide drugs, Zealand Pharma